Neos Therapeutics to Present at Upcoming Investor Conferences

DALLAS and FORT WORTH, Texas, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the following investor conferences:

  • 2016 RBC Capital Markets Healthcare Conference taking place in New York, February 23 - 24. The presentation is scheduled for Tuesday, February 23, at 3:05 p.m. ET.

  • Cowen and Company 36th Annual Health Care Conference taking place in Boston, March 7 - 9. The presentation is scheduled for Tuesday, March 8, at 10:00 a.m. ET.

  • BioCentury 23rd Annual Future Leaders in the Biotech Industry conference taking place in New York on March 11. Dr. Garg will present at 9:00 a.m. ET.

Live webcasts of these presentations will be available in the investor section of the company’s website, and will be archived on the website.

About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. The Company recently received FDA approval of Adzenys XR-ODTTM - the first and only FDA-approved amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two other branded product candidates in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the treatment of ADHD. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

1Tussionex® is a registered trademark of the UCB Group of Companies

CONTACTS: Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics (972) 408‐1389 David Carey, Investor Relations Lazar Partners (212) 867‐1768

Source:Neos Therapeutics, Inc